NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name (Ascending) | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
16571-0819-51 | 16571-0819 | Temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0819-41 | 16571-0819 | Temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0820-02 | 16571-0820 | Temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0820-51 | 16571-0820 | Temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0820-41 | 16571-0820 | Temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0821-02 | 16571-0821 | Temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0821-51 | 16571-0821 | Temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0821-41 | 16571-0821 | Temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
59923-0703-05 | 59923-0703 | temozolomide | TEMOZOLOMIDE | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0704-14 | 59923-0704 | temozolomide | TEMOZOLOMIDE | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0705-05 | 59923-0705 | temozolomide | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0706-14 | 59923-0706 | temozolomide | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0707-05 | 59923-0707 | temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0708-14 | 59923-0708 | temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0709-05 | 59923-0709 | temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0710-14 | 59923-0710 | temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0711-05 | 59923-0711 | temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0712-14 | 59923-0712 | temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0713-05 | 59923-0713 | temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
44087-5000-03 | 44087-5000 | Tepotinib Hydrochloride | TEPMETKO | 225.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | Feb. 3, 2021 | In Use | |
44087-5000-06 | 44087-5000 | Tepotinib Hydrochloride | TEPMETKO | 225.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | Feb. 3, 2021 | In Use | |
49281-0880-03 | 49281-0880 | BACILLUS CALMETTE-GUERIN SUBSTRAIN CONNAUGHT LIVE ANTIGEN | THERACYS | 81.0 mg/3mL | Immunotherapy | Biological Response Modifier | Live Vaccine | Intravesical | July 22, 2011 | May 8, 2017 | No Longer Used |
00052-0602-02 | 00052-0602 | BACILLUS CALMETTE-GUERIN | TICE BCG | 50.0 mg/50mL | Immunotherapy | Biological Response Modifier | Live Vaccine | Intravesical | Aug. 24, 1990 | In Use | |
51144-0003-01 | 51144-0003 | Tisotumab vedotin | TIVDAK | 40.0 mg/4mL | Immunotherapy | Drug Antibody Conjugate | Tissue factor | Intravenous | Sept. 20, 2021 | In Use | |
67457-0662-05 | 67457-0662 | TOPOTECAN | TOPOTECAN | 1.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 9, 2018 | Feb. 28, 2022 | No Longer Used |
Found 10,000 results in 9 milliseconds — Export these results